Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHASE: [89Zr]Zr-DFO-APAC in PAOD/CLI
NCT06204237Phase 1Recruiting
- Sponsor
- Aplagon
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Zirconium Zr-89 DFO-APAC in peripheral arterial occlusive disease (PAOD) and critical limb ischemia (CLI), sponsored by Aplagon. Primary endpoint: Incidence of Treatment Emergent Adverse Events up to 21 days. Started Feb 2024; status: recruiting.
02
Drugs
Zirconium Zr-89 DFO-APAC
03
Conditions
peripheral arterial occlusive disease (PAOD)critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT06204237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06204237.